Company patents
Mirati Therapeutics, Inc.
Mirati Therapeutics, Inc. demonstrates a strong and growing focus on core pharmaceutical development, with "Pharmaceutical Preparations" patents surging by 85.7% in 2025 and "Therapeutic Activity (Pharma)" growing by 33.3% in the same year, indicating a robust pipeline, despite the expected lower patent counts so far in 2026 across most categories due to partial year data. The company's primary emphasis remains on "Heterocyclic Compounds," which constitutes 60.4% of its total portfolio, showcasing a consistent commitment to novel chemical entities.
Patent Trend by Technology Area
Yearly patent publications since 2023
Product themes
Product-level themes inferred from filings since 2023, with category chips showing where each theme appears. Select a theme to filter the patents below.
96 US filings (since 2023) · 7 categories · 9 themes
Design and synthesis of acyclic or carbocyclic organic compounds that selectively modulate specific biological targets or pathways for the treatment of diseases.
Development of small molecules, often bifunctional (e.g., PROTACs) or molecular glues, that induce the ubiquitin-proteasome system or autophagy to selectively degrade specific disease-causing proteins.
Development of therapeutic approaches involving the genetic modification of cells (e.g., T cells, stem cells, macrophages) or the use of viral/non-viral vectors to deliver genetic material for disease treatment.
Therapeutic interventions that target immune checkpoint pathways to either enhance or suppress immune responses, often used in cancer immunotherapy or autoimmune diseases.
Delivery systems specifically engineered to administer advanced drug formulations (e.g., microparticles, biologics, extended-release systems) to achieve precise targeting, controlled release kinetics, or enhanced therapeutic efficacy within the body.
Therapeutic strategies employing nucleic acids (DNA, RNA, oligonucleotides) to modulate gene expression, deliver genetic material, or interfere with disease-causing pathways. Includes gene therapy using viral vectors.
Techniques for preparing and characterizing specific solid forms, such as crystal forms, salts, co-crystals, or amorphous forms, of active pharmaceutical ingredients to optimize properties like stability, solubility, and bioavailability.
Methods and intermediates for preparing complex organic molecules intended as active pharmaceutical ingredients (APIs), often involving multi-step synthesis and optimization of reaction pathways.
Processes and methodologies for the efficient and scalable preparation of complex heterocyclic compounds and their precursors, including specific reaction conditions, purification techniques, and intermediate compounds.
Patents
Showing 1-2 of 2
API Solid Form Engineering